专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20110091520A1 Sustained Release Intraocular Implants and Methods for Treating Ocular Neuropathies 有权
标题翻译：持续释放眼内植入物和治疗眼神经病变的方法
公开(公告)号：US20110091520A1
公开(公告)日：2011-04-21
申请号：US12955630
申请日：2010-11-29
申请人： Glenn T. Huang , Thierry Nivaggioli
发明人： Glenn T. Huang , Thierry Nivaggioli
IPC分类号： A61K31/5377 , A61F2/14 , A61P27/02
CPC分类号： A61K9/0051 , A61K31/5377
摘要： Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.
摘要翻译：生物相容性眼内植入物包括β-肾上腺素能受体拮抗剂和与β-肾上腺素能受体拮抗剂相关的聚合物，以促进β肾上腺素能受体拮抗剂延长一段时间的眼睛释放。 β肾上腺素能受体拮抗剂可以与可生物降解的聚合物基质例如两种可生物降解聚合物的基质相关联。植入物可以放置在眼睛中以治疗一种或多种眼部病症，例如眼部神经病，例如各种形式的青光眼。

42. 发明申请

US20080138382A1 SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS 有权
公开(公告)号：US20080138382A1
公开(公告)日：2008-06-12
申请号：US12031659
申请日：2008-02-14
申请人： Glenn T. Huang , Thierry Nivaggioli
发明人： Glenn T. Huang , Thierry Nivaggioli
IPC分类号： A61F2/14 , A61P27/02
CPC分类号： A61K9/0051 , A61K9/0092 , A61K31/573 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

43. 发明申请

US20080107712A1 OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS 有权
公开(公告)号：US20080107712A1
公开(公告)日：2008-05-08
申请号：US11931954
申请日：2007-10-31
申请人： Jane-Guo Shiah , Rahul Bhagat , Wendy Blanda , Thierry Nivaggioli , Lin Peng , David Chou , David Weber
发明人： Jane-Guo Shiah , Rahul Bhagat , Wendy Blanda , Thierry Nivaggioli , Lin Peng , David Chou , David Weber
IPC分类号： A61K9/00 , A61K31/56
CPC分类号： A61K31/573 , A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1694 , A61K9/204 , A61K31/56
摘要： The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

44. 发明申请

US20070203173A1 Stable formulations, and methods of their preparation and use 有权
标题翻译：稳定的制剂及其制备和使用方法
公开(公告)号：US20070203173A1
公开(公告)日：2007-08-30
申请号：US11704442
申请日：2007-02-09
申请人： Sreenivasu Mudumba , Thierry Nivaggioli , Sudeep Takhar
发明人： Sreenivasu Mudumba , Thierry Nivaggioli , Sudeep Takhar
IPC分类号： A61K31/4745
CPC分类号： A61K31/436 , A61K31/445 , A61K31/4745 , A61K33/00 , A61K45/06 , B01F13/02
摘要： Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.
摘要翻译：本文描述的是包含治疗剂的制剂，包括但不限于包含雷帕霉素的制剂，药物制剂，单位剂量形式，试剂盒，制剂的制备方法和使用制剂的方法。这些制剂和方法具有增加的稳定性。

45. 发明申请

US20050244468A1 Sustained release intraocular implants and related methods 有权
标题翻译：持续释放眼内植入物及相关方法
公开(公告)号：US20050244468A1
公开(公告)日：2005-11-03
申请号：US10837356
申请日：2004-04-30
申请人： Glenn Huang , Thierry Nivaggioli
发明人： Glenn Huang , Thierry Nivaggioli
IPC分类号： A61K9/00 , A61K31/00 , A61K31/573 , A61K45/06 , A61F2/00
CPC分类号： A61K9/0051 , A61K9/0092 , A61K31/573 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.
摘要翻译：生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。植入物可以放置在眼睛中以治疗一种或多种眼睛状况。类固醇从植入物中释放超过约两个月，可能会释放超过几年。

46. 发明申请

US20050244465A1 Drug delivery systems and methods for treatment of an eye 审中-公开
标题翻译：药物输送系统和治疗眼睛的方法
公开(公告)号：US20050244465A1
公开(公告)日：2005-11-03
申请号：US10837291
申请日：2004-04-30
申请人： Thierry Nivaggioli , Victoria Rogers
发明人： Thierry Nivaggioli , Victoria Rogers
IPC分类号： A61K9/00 , A61K31/5377
CPC分类号： A61K9/0051
摘要： Systems and methods are provided for treatment of an eye. The systems generally include controlled, delayed and or sustained release bioerodible implantable elements having multiple layers of different materials and/or different concentrations of materials. The elements generally include an inner layer, or core, including a therapeutic agent, and one or more outer layers made of polymeric materials, for example substantially pure polymeric materials. The core may include a polymeric material combined with an active agent beneficial in treating a condition of an eye. The elements may be structured such that surfaces of the core are exposed to the physiological environment of the eye when initially implanted within the eye, or may be structured such that the core is entirely enclosed within the outer layers when initially implanted within the eye.
摘要翻译：提供用于治疗眼睛的系统和方法。所述系统通常包括具有多层不同材料和/或不同浓度材料的受控，延迟和/或持续释放的可生物蚀解可植入元件。元件通常包括内层或芯，包括治疗剂，以及由聚合物材料制成的一个或多个外层，例如基本上纯的聚合材料。芯可以包括与有益于治疗眼睛状况的活性剂组合的聚合物材料。元件可以被构造成使得当最初植入眼睛时，芯的表面暴露于眼睛的生理环境，或者可以被构造成使得当最初植入眼睛内时，芯完全封闭在外层内。

47. 发明授权

US06395298B1 Gellan gum tablet coating 失效
标题翻译：结冷胶胶片
公开(公告)号：US06395298B1
公开(公告)日：2002-05-28
申请号：US09308043
申请日：1999-09-24
申请人： John Flanagan , George Colegrove , Thierry Nivaggioli
发明人： John Flanagan , George Colegrove , Thierry Nivaggioli
IPC分类号： A61K934
CPC分类号： A01C1/06 , A61K9/286 , A61K9/2886
摘要： A tablet coating comprising gellan gum is disclosed along with a process which comprises admixing gellan gum and water under effective shear conditions to prepare an aqueous gellan gum coating composition thereof whereby the aqueous gellan gum coating composition is applied in an adherent fashion to a placebo or a tablet containing a pharmaceutical to form a gellan gum coated placebo or gellan gum coated active drug.
摘要翻译：公开了包含吉兰糖胶的片剂包衣以及一种方法，该方法包括在有效的剪切条件下混合结冷胶和水，以制备其结构胶结胶涂料组合物，由此将结晶胶结糖涂料组合物以粘附的方式施用于安慰剂或片剂含有药物以形成结冷胶涂布的安慰剂或结冷胶涂布的活性药物。

48. 发明申请

US20130236525A1 Sustained release intraocular implants and related methods 有权
公开(公告)号：US20130236525A1
公开(公告)日：2013-09-12
申请号：US13840535
申请日：2013-03-15
申请人： Glenn T. Huang , Thierry Nivaggioli
发明人： Glenn T. Huang , Thierry Nivaggioli
IPC分类号： A61K9/00 , A61K31/58
CPC分类号： A61K9/0051 , A61K9/0092 , A61K31/573 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

49. 发明授权

US08409607B2 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods 有权
公开(公告)号：US08409607B2
公开(公告)日：2013-04-02
申请号：US12029425
申请日：2008-02-11
申请人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
发明人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

50. 发明授权

US08404267B2 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods 有权
公开(公告)号：US08404267B2
公开(公告)日：2013-03-26
申请号：US12029424
申请日：2008-02-11
申请人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
发明人： Patrick M. Hughes , Thomas C. Malone , Gerald W. De Vries , Jeffery L. Edelman , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式